Hello,
Yes, what you are seeing is real from ATH to ATL. This could be a bargain but only if ThermoGenisis Holdings pulls a rabbit out of the hat. Apparently news of late may just be that. Read some of the highlights below then decide for yourself.
First Quarter and Subsequent Achievements:
*Net revenues for the first quarter of 2020 increased to $3.2 million, up 8% compared to the same period in 2019.
*Gross profit for the first quarter was $1.5 million, an increase of 19% compared to the same period in 2019.
*On March 31, the Company submitted notification to the U.S. Food and Drug Administration (FDA) of its intention to register and market the ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit in accordance with Section IV. D. of the "Policy for Diagnostic Tests for Coronavirus Disease – 2019 during the Public Health Emergency," issued by FDA on March 16, 2020. ("Policy D").
*On April 15, the Company received an acknowledgment letter from the FDA, confirming that ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit has been appropriately validated for distribution under the Policy D guideline.
*The Company's joint venture, ImmuneCyte Life Sciences, Inc. (ImmuneCyte), acquired the worldwide intellectual property for the development of fully human antibody therapeutics for COVID-19, including four high-affinity monoclonal antibody drug candidates against SARS-CoV-2 and tools for screening and quantifying efficacy of such neutralizing antibodies.
Full Article
Good Luck
Cheers!
Be sure to follow, like, and check my profile out for more trade ideas!
Yes, what you are seeing is real from ATH to ATL. This could be a bargain but only if ThermoGenisis Holdings pulls a rabbit out of the hat. Apparently news of late may just be that. Read some of the highlights below then decide for yourself.
First Quarter and Subsequent Achievements:
*Net revenues for the first quarter of 2020 increased to $3.2 million, up 8% compared to the same period in 2019.
*Gross profit for the first quarter was $1.5 million, an increase of 19% compared to the same period in 2019.
*On March 31, the Company submitted notification to the U.S. Food and Drug Administration (FDA) of its intention to register and market the ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit in accordance with Section IV. D. of the "Policy for Diagnostic Tests for Coronavirus Disease – 2019 during the Public Health Emergency," issued by FDA on March 16, 2020. ("Policy D").
*On April 15, the Company received an acknowledgment letter from the FDA, confirming that ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit has been appropriately validated for distribution under the Policy D guideline.
*The Company's joint venture, ImmuneCyte Life Sciences, Inc. (ImmuneCyte), acquired the worldwide intellectual property for the development of fully human antibody therapeutics for COVID-19, including four high-affinity monoclonal antibody drug candidates against SARS-CoV-2 and tools for screening and quantifying efficacy of such neutralizing antibodies.
Full Article
Good Luck
Cheers!
Be sure to follow, like, and check my profile out for more trade ideas!
